ANGELA DAVIS: Open Payments
NPI 1740523919 · MARLTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,597 in 89 payments from 13 companies in 2025. Trend: 2023 $825 · 2024 $1,309 · 2025 $1,597
Food & beverage: $1,597
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $313 |
| Otsuka America Pharmaceutical, Inc. | 8 | $246 |
| ABBVIE INC. | 15 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $234 |
| Vanda Pharmaceuticals Inc. | 13 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $109 |
| Alkermes, Inc. | 4 | $80 |
| Lundbeck LLC | 3 | $51 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Integra LifeSciences Corporation | 1 | $34 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, FANAPT, TRINTELLIX, ARISTADA, COBENFY.
Industry payments across NJ — which companies pay providers there.
